Aminocandin
Star0
Identification
- Generic Name
- Aminocandin
- DrugBank Accession Number
- DB05128
- Background
Aminocandin is a new representative of the echinocandins that could potentially affect the cellular morphology and metabolic status of Candida albicans cells within biofilms.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 1102.297
Monoisotopic: 1101.57464826 - Chemical Formula
- C56H79N9O14
- Synonyms
- Not Available
- External IDs
- HMR-3270
- HMR3270
- IP-960
- IP960
- NXL-201
Pharmacology
- Indication
Investigated for use/treatment in fungal infections.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- 227472-48-2
- InChI Key
- UMNFJRNUJIBDSK-NMVZEWDOSA-N
- InChI
- InChI=1S/C56H79N9O14/c1-4-5-6-7-8-9-24-79-41-20-16-36(17-21-41)35-12-14-37(15-13-35)50(72)60-42-26-38(58-23-22-57)28-59-54(76)48-49(71)32(2)29-65(48)55(77)43(31-66)61-53(75)47(45(70)25-34-10-18-39(68)19-11-34)63-52(74)44-27-40(69)30-64(44)56(78)46(33(3)67)62-51(42)73/h10-21,32-33,38,40,42-49,58,66-71H,4-9,22-31,57H2,1-3H3,(H,59,76)(H,60,72)(H,61,75)(H,62,73)(H,63,74)/t32-,33+,38?,40+,42-,43-,44-,45+,46-,47-,48-,49-/m0/s1
- IUPAC Name
- N-[(3S,6S,9S,11R,15S,18S,24S,25S,26S)-20-[(2-aminoethyl)amino]-11,25-dihydroxy-6-[(1R)-1-hydroxy-2-(4-hydroxyphenyl)ethyl]-15-[(1R)-1-hydroxyethyl]-3-(hydroxymethyl)-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-4'-(octyloxy)-[1,1'-biphenyl]-4-carboxamide
- SMILES
- CCCCCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1CC(CNC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)CC1=CC=C(O)C=C1)NCCN
References
- General References
- Cateau E, Levasseur P, Borgonovi M, Imbert C: The effect of aminocandin (HMR 3270) on the in-vitro adherence of Candida albicans to polystyrene surfaces coated with extracellular matrix proteins or fibronectin. Clin Microbiol Infect. 2007 Mar;13(3):311-5. [Article]
- External Links
- PubChem Compound
- 16072305
- PubChem Substance
- 175426949
- ChemSpider
- 9854442
- ChEBI
- 84073
- Wikipedia
- Aminocandin
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0389 mg/mL ALOGPS logP 1.27 ALOGPS logP -2.1 Chemaxon logS -4.4 ALOGPS pKa (Strongest Acidic) 9.81 Chemaxon pKa (Strongest Basic) 9.21 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 16 Chemaxon Hydrogen Donor Count 13 Chemaxon Polar Surface Area 354.78 Å2 Chemaxon Rotatable Bond Count 19 Chemaxon Refractivity 288.69 m3·mol-1 Chemaxon Polarizability 117.73 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9229 Blood Brain Barrier - 0.987 Caco-2 permeable - 0.8006 P-glycoprotein substrate Substrate 0.8546 P-glycoprotein inhibitor I Non-inhibitor 0.7577 P-glycoprotein inhibitor II Non-inhibitor 0.5204 Renal organic cation transporter Non-inhibitor 0.8956 CYP450 2C9 substrate Non-substrate 0.8481 CYP450 2D6 substrate Non-substrate 0.8214 CYP450 3A4 substrate Substrate 0.6 CYP450 1A2 substrate Non-inhibitor 0.9571 CYP450 2C9 inhibitor Non-inhibitor 0.8926 CYP450 2D6 inhibitor Non-inhibitor 0.7887 CYP450 2C19 inhibitor Non-inhibitor 0.867 CYP450 3A4 inhibitor Non-inhibitor 0.7826 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9082 Ames test Non AMES toxic 0.727 Carcinogenicity Non-carcinogens 0.6991 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 3.1232 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9724 hERG inhibition (predictor II) Inhibitor 0.6616
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52